176 related articles for article (PubMed ID: 11925616)
1. Cloning of cytochrome P-450 2C9 cDNA from human liver and its expression in CHL cells.
Zhu GJ; Yu YN; Li X; Qian YL
World J Gastroenterol; 2002 Apr; 8(2):318-22. PubMed ID: 11925616
[TBL] [Abstract][Full Text] [Related]
2. Establishment of a transgenic cell line stably expressing human cytochrome P450 2C18 and identification of a CYP2C18 clone with exon 5 missing.
Zhu-Ge J; Yu YN; Qian YL; Li X
World J Gastroenterol; 2002 Oct; 8(5):888-92. PubMed ID: 12378636
[TBL] [Abstract][Full Text] [Related]
3. Stable expression of human cytochrome P450 2D6*10 in HepG2 cells.
Zhuge J; Yu YN; Wu XD
World J Gastroenterol; 2004 Jan; 10(2):234-7. PubMed ID: 14716830
[TBL] [Abstract][Full Text] [Related]
4. Heterologous expression of human cytochrome P450 2E1 in HepG2 cell line.
Zhuge J; Luo Y; Yu YN
World J Gastroenterol; 2003 Dec; 9(12):2732-6. PubMed ID: 14669323
[TBL] [Abstract][Full Text] [Related]
5. Cloning of UGT1A9 cDNA from liver tissues and its expression in CHL cells.
Li X; Yu YN; Zhu GJ; Qian YL
World J Gastroenterol; 2001 Dec; 7(6):841-5. PubMed ID: 11854913
[TBL] [Abstract][Full Text] [Related]
6. Catalytic activities of human cytochrome P450 2C9*1, 2C9*3 and 2C9*13.
Guo Y; Wang Y; Si D; Fawcett PJ; Zhong D; Zhou H
Xenobiotica; 2005 Sep; 35(9):853-61. PubMed ID: 16308280
[TBL] [Abstract][Full Text] [Related]
7. Relative quantities of catalytically active CYP 2C9 and 2C19 in human liver microsomes: application of the relative activity factor approach.
Venkatakrishnan K; von Moltke LL; Greenblatt DJ
J Pharm Sci; 1998 Jul; 87(7):845-53. PubMed ID: 9649353
[TBL] [Abstract][Full Text] [Related]
8. In vitro functional characterization of 37 CYP2C9 allelic isoforms found in Chinese Han population.
Dai DP; Wang YH; Wang SH; Geng PW; Hu LM; Hu GX; Cai JP
Acta Pharmacol Sin; 2013 Nov; 34(11):1449-56. PubMed ID: 24077631
[TBL] [Abstract][Full Text] [Related]
9. Identification and partial characterization of a novel CYP2C9 splicing variant encoding a protein lacking eight amino acid residues.
Ariyoshi N; Shimizu Y; Kobayashi Y; Nakamura H; Nakasa H; Nakazawa K; Ishii I; Kitada M
Drug Metab Pharmacokinet; 2007 Jun; 22(3):187-94. PubMed ID: 17603219
[TBL] [Abstract][Full Text] [Related]
10. Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes.
Yamazaki H; Inoue K; Shimada T
Xenobiotica; 1998 Feb; 28(2):103-15. PubMed ID: 9522436
[TBL] [Abstract][Full Text] [Related]
11. In vitro modulatory effects on three major human cytochrome P450 enzymes by multiple active constituents and extracts of Centella asiatica.
Pan Y; Abd-Rashid BA; Ismail Z; Ismail R; Mak JW; Pook PC; Er HM; Ong CE
J Ethnopharmacol; 2010 Jul; 130(2):275-83. PubMed ID: 20457244
[TBL] [Abstract][Full Text] [Related]
12. CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes.
Wester MR; Lasker JM; Johnson EF; Raucy JL
Drug Metab Dispos; 2000 Mar; 28(3):354-9. PubMed ID: 10681382
[TBL] [Abstract][Full Text] [Related]
13. Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily.
Veronese ME; Doecke CJ; Mackenzie PI; McManus ME; Miners JO; Rees DL; Gasser R; Meyer UA; Birkett DJ
Biochem J; 1993 Jan; 289 ( Pt 2)(Pt 2):533-8. PubMed ID: 8424795
[TBL] [Abstract][Full Text] [Related]
14. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism.
Sullivan-Klose TH; Ghanayem BI; Bell DA; Zhang ZY; Kaminsky LS; Shenfield GM; Miners JO; Birkett DJ; Goldstein JA
Pharmacogenetics; 1996 Aug; 6(4):341-9. PubMed ID: 8873220
[TBL] [Abstract][Full Text] [Related]
15. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.
Lasker JM; Wester MR; Aramsombatdee E; Raucy JL
Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596
[TBL] [Abstract][Full Text] [Related]
16. Discovery of new potentially defective alleles of human CYP2C9.
Blaisdell J; Jorge-Nebert LF; Coulter S; Ferguson SS; Lee SJ; Chanas B; Xi T; Mohrenweiser H; Ghanayem B; Goldstein JA
Pharmacogenetics; 2004 Aug; 14(8):527-37. PubMed ID: 15284535
[TBL] [Abstract][Full Text] [Related]
17. Stimulation of tolbutamide hydroxylation by acetone and acetonitrile in human liver microsomes and in a cytochrome P-450 2C9-reconstituted system.
Palamanda J; Feng WW; Lin CC; Nomeir AA
Drug Metab Dispos; 2000 Jan; 28(1):38-43. PubMed ID: 10611138
[TBL] [Abstract][Full Text] [Related]
18. Clinical drugs undergoing polymorphic metabolism by human cytochrome P450 2C9 and the implication in drug development.
He SM; Zhou ZW; Li XT; Zhou SF
Curr Med Chem; 2011; 18(5):667-713. PubMed ID: 21182487
[TBL] [Abstract][Full Text] [Related]
19. Cynomolgus monkey cytochrome P450 2C43: cDNA cloning, heterologous expression, purification and characterization.
Mitsuda M; Iwasaki M; Asahi S
J Biochem; 2006 May; 139(5):865-72. PubMed ID: 16751594
[TBL] [Abstract][Full Text] [Related]
20. No major difference in inhibitory susceptibility between CYP2C9.1 and CYP2C9.3.
Hanatani T; Fukuda T; Onishi S; Funae Y; Azuma J
Eur J Clin Pharmacol; 2003 Jul; 59(3):233-5. PubMed ID: 12756514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
